When an adult asks a doctor for help quitting cigarettes, what options should be on the table? 

A paper published in JAMA on July 30, 2026, argues that nicotine e-cigarettes should be included in that discussion. The authors recommend giving patients an evidence-informed explanation of vaping alongside other smoking cessation treatments. 

The publication, Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians, was developed by a working group within the Society for Research on Nicotine and Tobacco’s Treatment Research Network. 

 

A Review of the Evidence With Practical Recommendations 

This paper is a Special Communication, rather than a new clinical trial. Its purpose is to bring existing research into the clinical conversation and help healthcare professionals discuss nicotine e-cigarettes with adults who currently smoke. 

That makes its focus practical: how should clinicians explain the evidence, address misunderstandings, and help patients make informed decisions? 

The authors conclude that nicotine e-cigarettes are less harmful than cigarettes and have demonstrated greater effectiveness for smoking cessation than nicotine replacement therapies. They also identify misconceptions about vaping risks among clinicians as an obstacle to informed discussions. 

 

What Does the Broader Cessation Evidence Show? 

The paper’s conclusions sit within a growing body of research examining whether nicotine e-cigarettes help adults stop smoking. 

An updated Cochrane review published in August 2026, after the JAMA paper appeared online, provides additional context. It found high-certainty evidence that nicotine e-cigarettes lead to higher quit rates than nicotine replacement therapy, including patches and gum. 

Cochrane reported approximately four additional people quitting for every 100 using nicotine e-cigarettes instead of NRT. 

That finding needs to be read accurately. It describes an average difference across research studies. It does not guarantee that an individual will quit, establish that every device performs equally, or mean nicotine replacement therapy does not work. 

For readers evaluating the headlines, the relevant question is the comparison being made. Evidence of higher quit rates than NRT is a specific finding about cessation effectiveness—not a declaration that vaping is harmless. 

 

What the Authors Want Clinicians to Do 

The JAMA authors’ overarching recommendation is to integrate e-cigarettes into conversations about evidence-based smoking cessation treatment. 

Their framework includes shared decision-making, discussion of risks and benefits, questions to guide patient conversations, and practical guidance on using e-cigarettes to quit smoking. 

Our interpretation is that this places greater responsibility on the quality of the conversation. Simply asking whether a patient vapes is different from understanding whether they are trying to stop smoking, what they believe about relative risks, and what support they need. 

It also creates room for a distinction that is often lost in public debate: discussing vaping with an adult who currently smokes involves a different clinical situation from discussing nicotine initiation with someone who has never smoked. 

 

Relative Risk Needs a Clear Explanation 

The FDA’s explanation of tobacco product risks recognizes that tobacco products carry different levels of risk. It also emphasizes that no tobacco product is safe. 

For adults who smoke and choose to switch to a less harmful tobacco product, the agency stresses the importance of switching completely away from cigarettes to obtain the full potential health benefit. Youth and people who do not use tobacco should not begin using e-cigarettes. 

Those points can coexist. Acknowledging that vaping carries risks does not require treating it as equivalent to cigarette smoking. Recognizing a potential benefit for adults who smoke does not justify encouraging nicotine use among people who do not. 

 

Clinical Evidence and FDA Approval Are Separate Questions 

Readers should also distinguish research findings from regulatory status. 

FDA marketing authorization for an e-cigarette concerns its sale as a tobacco product. Products marketed for therapeutic purposes, such as helping people quit smoking, fall under a different regulatory framework. 

The FDA continues to recommend approved cessation medications and behavioral counseling as first-line treatment. It notes that combining counseling with medication increases the likelihood of quitting. 

Publication of clinical recommendations does not change those regulatory distinctions or establish a cessation claim for a particular retail product. 

 

Why This Paper Deserves Attention 

For us, the paper’s significance is its call for a more informed discussion in the exam room. 

Adults trying to stop smoking need explanations that distinguish effectiveness, relative risk, uncertainty, and regulatory approval. Those are separate questions, and each deserves a clear answer. 

The recommendations published in JAMA give clinicians a framework for having that conversation. They also give readers a reason to look beyond sweeping claims about vaping and ask what the evidence actually says about adults who are trying to leave cigarettes behind. 

Primary source: Leavens ELS, Pebley K, Smith TT, et al. Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians. JAMA. 2026;336(9):783–790. Read the publication. 

This article discusses research and clinical recommendations. It is not individualized medical advice or a cessation claim for any product sold by Mi-Pod.